The proceeds from this financing will be used to advance its lead selective mTORC1 inhibitor, AE116, from the preclinical stage through clinical proof of concept for an undisclosed rare disease of the central nervous system.
Richard Gaster, MD, PhD, Principal at venBio, and Mike Powell, PhD, managing general partner at Sofinnova Investments, will join Jens Eckstein, PhD, managing partner at Apollo Health Ventures on Aeovian's board of directors.
Yvonne Yamanaka, PhD, vice president at venBio, and Sarah Bhagat, PhD, Principal at Sofinnova, will join as Board Observers.
Aeovian's proprietary platform is supported by an extensive intellectual property portfolio, part of which has been obtained by assignment from the Buck Institute of Novato, California, the nation's first independent research facility focused solely on understanding the connection between aging and chronic disease.
Aeovian Pharmaceuticals, Inc. focuses on the discovery and development of novel, highly selective mTORC1 inhibitors for the treatment of rare and age-related diseases.
The company was founded with technology licensed from The Buck Institute for Research on Aging. Aeovian's lead candidates are poised to overcome the clinical limitations of current mTOR inhibitors, namely their deleterious side effects on metabolic health and immune function that arise from their off-target inhibition of mTORC2.
Aeovian's lead compounds are novel, highly selective modulators of the mTORC1 pathway with the potential to address multiple underlying causes of disease initiation and progression, such as oxidative, cellular, and environmental stress.
venBio Partners is a life sciences investment firm that partners with industry leaders to build innovative medicines and technologies, with a focus on novel therapeutics for unmet medical needs.
Sofinnova Investments is a biopharmaceutical investment firm with approximately USD 2.1bn in assets under management.
Apollo Health Ventures is an early-stage investment firm based in Europe and the US focusing on translating breakthrough discoveries in geroscience.
Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches through highest quality stand-alone and integrated drug discovery and development solutions.
Nuvalent commences NVL-655 phase 2 clinical trial in subjects with NSCLC and other solid tumours
GC Biopharma's GC1130A receives EMA Orphan Drug Designation
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Newron enrols 290 patients in schizophrenia study
Vistagen granted European patent for AV-101 to treat neuropathic pain
GenSight Biologics reports business and financial update
Alora Pharmaceuticals announces Relexxii commercial launch
IGC Pharma granted patent for Alzheimer's drug formulation
NRx Pharmaceuticals signs data agreement with Columbia University for IV Ketamine trials